Request FREE sample PDF
Pharmacy benefit management market
DNA Testing & Diagnostics Market Report Overview
Global DNA Testing and Diagnostics Market size was USD 13.9 Billion in 2023 and market is projected to touch 37.5 Billion by 2032, exhibiting a CAGR of 11.6% during the forecast period. In the market study, our analysts have considered dna testing and diagnostics players such as GE Healthcare, 454 Life Sciences, Abbott Laboratories, Beckman Coulter, Bio-Rad Laboratories, Thermo Fisher Scientific, Illumina, Cephide, Hologic, Transgenomic, Siemens Healthcare, Roche Diagnostics, Qiagen, Affymetrix, Agilent Technologies
DNA testing and diagnostics is a medical test that can find mutations in one’s proteins, chromosomes, or genes. These mutations can tell if one has a genetic condition or not. Additionally, DNA tests can determine your risk of inheriting a genetic disorder or developing a particular condition. The genetic diagnosis of susceptibility to inherited diseases and the determination of bloodlines are both aspects of DNA testing & diagnostics.
Market players have disclosed innovative techniques for developing new treatments with a focused strategies. Growing healthcare infrastructure, increasing global awareness of personalized and preventative medicine and diagnosis, treatments with high success rate, and rising investment by manufacturers are factors that will help to increase demand for DNA testing & diagnostics.
COVID-19 Impact: Pandemic Affected the Market Negatively
Due to the COVID-19 pandemic, a lockdown was imposed, preventing a variety of businesses and utilities from producing, processing, and importing and exporting. However, Pandemic had a negative impact on the growth of DNA testing & diagnostics market due to lack of genetic counsellors to look after patients and laboratories were not running as per government regulations. Risk of transmission through contact of testing devices negatively impacted the growth of market.
Latest Trends
"Awareness Regarding the Benefits of DNA testing & Diagnostics to drive Market Growth "
Rising healthcare development, sophisticated infrastructure facilities, increase in the number of skilled doctors, awareness regarding benefits of DNA testing are expected to boost the growth of market during the forecast period. ColoClear by Circle (ColoClear), a cutting-edge, non-invasive at-home screening test for spotting colorectal cancer's early warning signals, was introduced in June 2022 by Prenetics Group Limited, a pioneer in genomic and diagnostic testing. A cancer test that examines a large number of tumor genes in a single tissue sample was introduced in Europe by the genome sequencing company Illumina in March 2022. This test has the potential to assist patients with uncommon disorders in locating appropriate treatment options. These recent developments are anticipated to drive market growth.
DNA Testing & Diagnostics Market Segmentation
- By Type Analysis
According to type, the market can be segmented into PCR-Based Diagnostics, ISH Diagnostics and NGS DNA Diagnosis.
- By Application Analysis
Based on application, the market can be divided into Hospital, Medical Research, and Pharmacogenomics Diagnostic Testing.
Driving Factors
"Increasing Prevalence Genetic Disease to Drive Market Demand"
Healthcare expenses have been increasing over the years. A person's lifetime risk of developing various types of cancer can be determined with the assistance of genetic testing. There are genetic tests available to look for inherited variants and mutations in the DNA sequence that could cause cells to grow too much and cause cancer. Increase in the occurrence of different genetic diseases and rising consciousness among people regarding the benefits of DNA testing, developments in healthcare sector, and highly advanced devices are responsible to boost the DNA testing & diagnostics market growth.
"Healthcare technological developments will boost market expansion"
The healthcare sector has expanded and medical facilities have developed in ways that make it possible to produce testing and diagnostic tools of high quality and at a reasonable cost. In order to gain market share, the major players in the business are also developing fresh concepts and innovations. In order to draw customers, they are presenting a variety of new products. This is anticipated to fuel market expansion.
Restraining Factors
"High Cost of R&D to Restrict Market Demand"
It is anticipated that the high cost of research and development (R&D) associated with the development and application of alternative methods will limit industry expansion to some extent. Additionally, it is anticipated that unclear reimbursement structures and stringent government regulations regarding DNA prototyping will impede the entry of new market players. These factors are responsible to hinder the growth of market.
DNA Testing & Diagnostics Market Regional Insights
"Increase in the Use of DNA diagnostics in North America to Expand Market Size"
As a result of growing use of DNA diagnostics and the incidence of many chronic and infectious disorders and rapid technological advancements in North America, it is considered to be the most dominating region in DNA testing & diagnostics market share. The main element anticipated to contribute to the industry growth is the introduction of new products by key players, improved healthcare infrastructure, strong government initiatives.
Key Industry Players
"Key Players Implementing Innovative Strategies to Influence Market Development"
Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. The top key players in the market are GE Healthcare, 454 Life Sciences, Abbott Laboratories, Beckman Coulter, Bio-Rad Laboratories, Thermo Fisher Scientific, Illumina, Cephide, Hologic and others. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios. In addition, the strategies to develop new technologies, capital investment in R&D, improve product quality, acquisitions, mergers, and compete for the market competition help them to perpetuate their position and value in the market. Besides, collaboration with other companies & extensive possession over market shares by the key players stimulates the market demand.
LIST OF TOP DNA TESTING & DIAGNOSTICS COMPANIES
- GE Healthcare
- 454 Life Sciences
- Abbott Laboratories
- Beckman Coulter
- Bio-Rad Laboratories
- Thermo Fisher Scientific
- Illumina
- Cephide
- Hologic
- Transgenomic
- Siemens Healthcare
- Roche Diagnostics
- Qiagen
- Affymetrix
- Agilent Technologies
Report Coverage
This report examines an understanding of the DNA testing & diagnostics market’s size, share, growth rate, segmentation by type, application, key players, and previous and current market scenarios. The report also collects the market’s precise data and forecasts by market experts. Also, it describes the study of this industry’s financial performance, investments, growth, innovation marks, and new product launches by the top companies and offers deep insights into the current market structure, competitive analysis based on key players, key driving forces, and restraints that affect the demand for growth, opportunities, and risks.
Furthermore, the post-COVID-19 pandemic’s effects on international market restrictions and a deep understanding of how the industry will recover, and strategies are also stated in the report. The competitive landscape has also been examined in detail to provide clarification of the competitive landscape.
This report also discloses the research based on methodologies that define price trend analysis of target companies, collection of data, statistics, target competitors, import-export, information, and previous years’ records based on market sales. Moreover, all the significant factors which influence the market such as small or medium business industry, macro-economic indicators, value chain analysis, and demand-side dynamics, with all the major business players have been explained in detail. This analysis is subject to modification if the key players and feasible analysis of market dynamics change.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 13.9 Billion in 2023 |
Market Size Value By |
US$ 37.5 Billion by 2032 |
Growth Rate |
CAGR of 11.6% from 2023 to 2032 |
Forecast Period |
2023-2032 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered | |
By Type
|
|
By Application
|
Frequently Asked Questions
-
What value is the global DNA testing & diagnostics market expected to touch by 2032?
The global DNA testing & diagnostics market is expected to touch USD 37.5 Billion by 2032.
-
What CAGR is the DNA testing & diagnostics market expected to exhibit during 2023-2032?
The DNA testing & diagnostics market is expected to exhibit a CAGR of 11.6% over 2023-2032.
-
Which are the driving factors of the DNA Testing & Diagnostics Market?
Rising incidences of genetic diseases, reduction in prices of genetic sequencing are the driving factors of DNA Testing & Diagnostics Market.
-
Which are the top companies operating in the DNA Testing & Diagnostics Market?
GE Healthcare, 454 Life Sciences, Abbott Laboratories, Beckman Coulter, Bio-Rad Laboratories, Thermo Fisher Scientific, Illumina, Cephide, Hologic